Compare Amphastar Pharmaceuticals Inc (AMPH) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Alphabet Inc Class A — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Alphabet Inc Class A trades at $345.78 (market cap $4.36T). The key difference: Alphabet Inc Class A is far larger — about 5046.6× Amphastar Pharmaceuticals Inc's market cap, and Alphabet Inc Class A pays a 0.25% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | GOOGL | |
|---|---|---|
Market Cap | $863.95M | $4.36T |
Sector | Health | Media |
52-Week High | $30.81 | $402.62 |
52-Week Low | $16.87 | $199.32 |
Enterprise Value | $1.26B | $4.25T |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Alphabet (GOOGL) trades at $357.52, up 0.91% with strong technical momentum as it approaches resistance near $359. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $9.11 versus $2.87, revenue growth from $402.84B in 2025 to projected $445.9B in 2026, and improving profit margins. Recent developments include YouTube subscription price increases and strategic AI partnerships with Intel and Anthropic, positioning the company for continued growth in the digital advertising and cloud computing sectors.
Alphabet presents a compelling investment case with 85% analyst buy ratings and a $426.28 consensus price target representing 19% upside potential. Key opportunities include AI-driven revenue growth and expanding cloud market share, while risks involve antitrust scrutiny and competitive pressures in digital advertising. The stock's current valuation at 17.94 P/E appears reasonable given the company's strong earnings trajectory and market leadership position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
